Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
This article was originally published in RPM Report
Executive Summary
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
You may also be interested in...
Pfizer On Obamacare Rewind: No Short-Term Impact On Industry
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
Pfizer On Obamacare Rewind: No Short-Term Impact On Industry
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
Drug Pricing ‘Solutions’ Coming In Future Phase Of US Healthcare Reform, Sec. Price Says
Trump tweets about plans for 'new system where there will be competition' to address Rx costs as Republican effort to repeal and replace the Affordable Care Act officially gets underway with release of two House bills.